Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events
Martin O’Donnell(Ollscoil na Gaillimhe – University of Galway), Roland E. Schmieder, Andrew Mente(Hamilton Health Sciences), Johannes F.E. Mann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Koon Teo(Population Health Research Institute), Jeffrey L. Probstfield(National Heart Lung and Blood Institute), Antonio Dans(University of the Philippines Manila), Peggy Gao, Peter Sleight(Hamilton General Hospital), Arya M. Sharma(Rutgers, The State University of New Jersey), Matthew McQueen(Population Health Research Institute), Salim Yusuf(Population Health Research Institute)
Cited by 566
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
|The Lancet|2005|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k